This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ndembi, N.
Right arrow Articles by Arts, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ndembi, N.
Right arrow Articles by Arts, E. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2008, p. 177-184, Vol. 46, No. 1
0095-1137/08/$08.00+0     doi:10.1128/JCM.00428-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaoundé, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B{triangledown}

Nicaise Ndembi,1* Awet Abraha,2 Heather Pilch,2 Hiroshi Ichimura,3 Dora Mbanya,1 Lazare Kaptue,1 Robert Salata,2 and Eric J. Arts2

Laboratory of Hematology and Virology, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon,1 Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, 2109 Adelbert Rd., Cleveland, Ohio 44195,2 Department of Viral Infection and International Health, School of Medicine, Kanazawa University, Kanazawa, Japan3

Received 24 February 2007/ Returned for modification 14 August 2007/ Accepted 3 September 2007

Prior to current studies on the emergence of drug resistance with the introduction of antiretroviral therapy (ART) in Cameroon, we performed genotypic analysis on samples from drug-naïve, human immunodeficiency virus (HIV)-infected individuals in this country. Of the 79 HIV type 1 (HIV-1) pol sequences analyzed from Cameroonian samples, 3 (3.8%) were identified as HIV-1 group O, 1 (1.2%) was identified as an HIV-2 intergroup B/A recombinant, and the remaining 75 (95.0%) were identified as HIV-1 group M. Group M isolates were further classified as subtypes A1 (n = 4), D (n = 4), F2 (n = 6), G (n = 12), H (n = 2), and K (n = 1) and as circulating recombinant forms CRF02_AG (n = 41), CRF11_cpx (n = 1), and CRF13_cpx (n = 2). Two pol sequences were identified as unique recombinant forms of CRF02_AG/F2 (n = 2). M46L (n = 2), a major resistance mutation associated with resistance to protease inhibitors, was observed in 2/75 (2.6%) group M samples. Single mutations associated with resistance to nucleoside reverse transcriptase inhibitors (T215Y/F [n = 3]) and nonnucleoside reverse transcriptase inhibitors (V108I [n = 1], L100I [n = 1], and Y181C [n = 2]) were observed in 7 of 75 (9.3%) group M samples. None of the patients had any history of ART exposure. Population surveillance of transmitted HIV drug resistance is required and should be included to aid in the development of appropriate guidelines.

* Corresponding author. Present address: Medical Research Council (UK), c/o Uganda Virus Research Institute, P.O. Box 49, Entebbe, Uganda. Phone: 237-952-31-17. Fax: 237-220-90-75. E-mail: ndembinic{at}yahoo.fr

{triangledown} Published ahead of print on 12 September 2007.

Journal of Clinical Microbiology, January 2008, p. 177-184, Vol. 46, No. 1
0095-1137/08/$08.00+0     doi:10.1128/JCM.00428-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»